HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway

References

• Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28:1254-61; PMID:20100961; http://dx.doi.org/10.1200/JCO.2009.24.6116
   PubMed Web of Science ®Google Scholar
• Gourdier I, Del Rio M, Crabbe L, Candeil L, Copois V, Ychou M, Auffray C, Martineau P, Mechti N, Pommier Y, et al. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 2002; 529:232-6; PMID:12372606; http://dx.doi.org/10.1016/S0014-5793(02)03347-1
   PubMed Web of Science ®Google Scholar
• Napier MP, Ledermann JA. Novel chemotherapeutic agents in colorectal cancer. Eur J Surg Oncol 2000; 26:605-10; PMID:11034814; http://dx.doi.org/10.1053/ejso.2000.0955
   PubMed Web of Science ®Google Scholar
• Waters J, Cunningham D. The changing face of chemotherapy in colorectal cancer. Br J Cancer 2001; 84:1-7; PMID:11139304; http://dx.doi.org/10.1054/bjoc.2000.1552
   PubMed Web of Science ®Google Scholar
• Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst 2009; 101:1543-52; PMID:19841331; http://dx.doi.org/10.1093/jnci/djp328
   PubMed Web of Science ®Google Scholar
• Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 2002; 3:75-82; PMID:11902527; http://dx.doi.org/10.1016/S1470-2045(02)00648-4
   PubMed Web of Science ®Google Scholar
• Poston GJ, Figueras J, Giuliante F, Nuzzo G, Sobrero AF, Gigot JF, Nordlinger B, Adam R, Gruenberger T, Choti MA, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 26:4828-33; PMID:18711170; http://dx.doi.org/10.1200/JCO.2008.17.6453
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30; PMID:14665611; http://dx.doi.org/10.1200/JCO.2004.09.046
   PubMed Web of Science ®Google Scholar
• Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 2005; 31:90-105; PMID:15847979; http://dx.doi.org/10.1016/j.ctrv.2004.12.006
   PubMed Web of Science ®Google Scholar
• Wakasugi T, Izumi H, Uchiumi T, Suzuki H, Arao T, Nishio K, Kohno K. ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene 2007; 26:5194-03; PMID:17297437; http://dx.doi.org/10.1038/sj.onc.1210326
   PubMed Web of Science ®Google Scholar
• Livesey KM, Tang D, Zeh HJ, Lotze MT. Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs 2009; 10:1269-79; PMID:19943199
   PubMed Web of Science ®Google Scholar
• White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009; 15:5308-16; PMID:19706824; http://dx.doi.org/10.1158/1078-0432.CCR-07-5023
   PubMed Web of Science ®Google Scholar
• Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Lotze MT, et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011; 25:23-31; PMID:20927132; http://dx.doi.org/10.1038/leu.2010.225
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29:5299-310; PMID:20622903; http://dx.doi.org/10.1038/onc.2010.261
   PubMed Web of Science ®Google Scholar
• Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5:331-42; PMID:15803152; http://dx.doi.org/10.1038/nri1594
   PubMed Web of Science ®Google Scholar
• Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, Zhang L, Manfredi JJ, Zeh HJ 3rd, Li L, et al. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res 2012; 72:1996-2005; PMID:22345153; http://dx.doi.org/10.1158/0008-5472.CAN-11-2291
   PubMed Web of Science ®Google Scholar
• Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 2007; 1773:1213-26; PMID:17112607; http://dx.doi.org/10.1016/j.bbamcr.2006.10.005
   PubMed Web of Science ®Google Scholar
• Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet 2010; 375:1030-47; PMID:20304247; http://dx.doi.org/10.1016/S0140-6736(10)60353-4
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Xiu P, Dong X, Xu Z, Zhu H, Liu F, Wei Z, Zhai B, Kanwar JR, Jiang H, Li J, et al. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Sci 2013; 104:375-82; PMID:23279642; http://dx.doi.org/10.1111/cas.12088
   PubMed Web of Science ®Google Scholar
• Ekblad L, Johnsson A. Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer. Anticancer Res 2012; 32:783-6; PMID:22399593
   PubMed Web of Science ®Google Scholar
• el-akawi Z, Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 1996; 105:5-14; PMID:8689632; http://dx.doi.org/10.1016/0304-3835(96)04245-0
   PubMed Web of Science ®Google Scholar
• Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001; 48:398-406; PMID:11761458; http://dx.doi.org/10.1007/s002800100363
   PubMed Web of Science ®Google Scholar
• Iwatsuki M, Mimori K, Yokobori T, Tanaka F, Tahara K, Inoue H, Baba H, Mori M. A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer. J Surg Oncol 2009; 100:261-6; PMID:19330779; http://dx.doi.org/10.1002/jso.21275
   PubMed Web of Science ®Google Scholar
• Vie N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, Fraslon C, Conseiller E, Molina F, Larroque C, et al. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol Cancer 2008; 7:14; PMID:18221502; http://dx.doi.org/10.1186/1476-4598-7-14
   PubMed Web of Science ®Google Scholar
• Ji C, Yang YL, Yang Z, Tu Y, Cheng L, Chen B, Xia JP, Sun WL, Su ZL, He L, et al. Perifosine sensitizes UVB-induced apoptosis in skin cells: new implication of skin cancer prevention? Cell Signal 2012; 24:1781-9; PMID:22584119; http://dx.doi.org/10.1016/j.cellsig.2012.05.003
   PubMed Web of Science ®Google Scholar
• Ji C, Yang B, Yang Z, Tu Y, Yang YL, He L, Bi ZG. Ultra-violet B (UVB)-induced skin cell death occurs through a cyclophilin D intrinsic signaling pathway. Biochem Biophys Res Commun 2012; 425:825-9; PMID:22892127; http://dx.doi.org/10.1016/j.bbrc.2012.07.160
   PubMed Web of Science ®Google Scholar
• Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004; 6:731-40; PMID:15235609; http://dx.doi.org/10.1038/ncb1151
   PubMed Web of Science ®Google Scholar
• Liu F, Zhang Y, Peng Z, Gao H, Xu L, Chen M. High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med 2012; 10:135; PMID:22747650; http://dx.doi.org/10.1186/1479-5876-10-135
   PubMed Web of Science ®Google Scholar